Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: an international observational study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
JHEP reports. - (2024) , 101216, ISSN: 2589-5559
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2024
- Creator
-
Xia, Dongdong
Bai, Wei
Wang, Qiuhe
Chung, Jin Wook
Adhoute, Xavier
Klöckner, Roman Trutz
Zhang, Hui
Bettinger, Dominik
Han, Guohong
- DOI
-
10.1016/j.jhepr.2024.101216
- URN
-
urn:nbn:de:bsz:25-freidok-2604933
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Xia, Dongdong
- Bai, Wei
- Wang, Qiuhe
- Chung, Jin Wook
- Adhoute, Xavier
- Klöckner, Roman Trutz
- Zhang, Hui
- Bettinger, Dominik
- Han, Guohong
- Universität
Time of origin
- 2024
Other Objects (12)
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Routine colonoscopy in patients with high risk of non-occlusive mesenteric ischemia
Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study